60 Degrees Pharmaceuticals Inc (SXTP)

Apr 22, 2025, 8:44 AM EDT - 2 days ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 10, 2025, 8:31 AM EDT - 14 days ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 8, 2025, 8:31 AM EDT - 16 days ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Feb 21, 2025, 9:00 AM EST - 2 months ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

Feb 20, 2025, 10:36 AM EST - 2 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 11, 2025, 12:59 PM EST - 2 months ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 6, 2025, 2:07 PM EST - 2 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 2 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 2 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 8:01 AM EST - 3 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 8, 2025, 8:02 AM EST - 3 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Dec 23, 2024, 8:57 AM EST - 4 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 11, 2024, 8:56 AM EST - 4 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 2, 2024, 4:05 PM EST - 5 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

Nov 22, 2024, 9:00 AM EST - 5 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nov 14, 2024, 2:31 PM EST - 5 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Oct 3, 2024, 9:02 AM EDT - 7 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Sep 12, 2024, 7:19 AM EDT - 8 months ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

Sep 4, 2024, 8:00 AM EDT - 8 months ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Aug 28, 2024, 2:48 PM EDT - 8 months ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2024, 11:01 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 12, 2024, 9:12 AM EDT - 9 months ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 6, 2024, 9:26 AM EDT - 9 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Jul 25, 2024, 9:02 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 19, 2024, 8:29 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 9, 2024, 6:31 AM EDT - 10 months ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jun 27, 2024, 7:59 AM EDT - 10 months ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

May 30, 2024, 7:59 AM EDT - 11 months ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 15, 2024, 1:45 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 8, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Apr 3, 2024, 7:58 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Mar 14, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

Feb 20, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Feb 8, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Jan 31, 2024, 12:00 PM EST - 1 year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 31, 2024, 11:15 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Jan 30, 2024, 9:45 AM EST - 1 year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Jan 22, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Jan 16, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

Dec 26, 2023, 7:59 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Nov 15, 2023, 7:29 AM EST - 1 year ago

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Oct 19, 2023, 8:31 AM EDT - 1 year ago

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

Oct 12, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

Sep 18, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Sep 6, 2023, 7:31 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 1, 2023, 9:00 AM EDT - 1 year ago

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

GENE

Aug 30, 2023, 7:32 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity